ATE353318T1 - Neue indolderivate mit affinität zum 5-ht6- rezeptor - Google Patents

Neue indolderivate mit affinität zum 5-ht6- rezeptor

Info

Publication number
ATE353318T1
ATE353318T1 AT02735394T AT02735394T ATE353318T1 AT E353318 T1 ATE353318 T1 AT E353318T1 AT 02735394 T AT02735394 T AT 02735394T AT 02735394 T AT02735394 T AT 02735394T AT E353318 T1 ATE353318 T1 AT E353318T1
Authority
AT
Austria
Prior art keywords
affinity
receptor
indole derivatives
new indole
new
Prior art date
Application number
AT02735394T
Other languages
English (en)
Inventor
Colin Charles Beard
Robin Douglas Clark
Lawrence Emerson Fisher
Ralph New Harris Iii
David Bruce Repke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE353318T1 publication Critical patent/ATE353318T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT02735394T 2001-06-07 2002-05-29 Neue indolderivate mit affinität zum 5-ht6- rezeptor ATE353318T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29670501P 2001-06-07 2001-06-07
US34021201P 2001-12-13 2001-12-13

Publications (1)

Publication Number Publication Date
ATE353318T1 true ATE353318T1 (de) 2007-02-15

Family

ID=26969776

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02735394T ATE353318T1 (de) 2001-06-07 2002-05-29 Neue indolderivate mit affinität zum 5-ht6- rezeptor

Country Status (32)

Country Link
US (3) US6787535B2 (de)
EP (1) EP1401813B1 (de)
JP (1) JP4187642B2 (de)
KR (1) KR100600240B1 (de)
CN (1) CN1257892C (de)
AR (1) AR036233A1 (de)
AT (1) ATE353318T1 (de)
AU (1) AU2002310747B2 (de)
BG (1) BG108420A (de)
BR (1) BR0210929A (de)
CA (1) CA2449874C (de)
CO (1) CO5630036A2 (de)
CZ (1) CZ20033529A3 (de)
DE (1) DE60218037T2 (de)
ES (1) ES2280546T3 (de)
HR (1) HRP20030984A2 (de)
HU (1) HUP0401307A2 (de)
IL (1) IL158997A0 (de)
MA (1) MA27032A1 (de)
MX (1) MXPA03011244A (de)
NO (1) NO20035359D0 (de)
NZ (1) NZ529631A (de)
PA (1) PA8546601A1 (de)
PE (1) PE20030039A1 (de)
PL (1) PL367305A1 (de)
RU (1) RU2294932C2 (de)
SK (1) SK16052003A3 (de)
TW (1) TW591015B (de)
UY (1) UY27322A1 (de)
WO (1) WO2002098857A1 (de)
YU (1) YU96103A (de)
ZA (1) ZA200309005B (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144883B2 (en) 2001-06-11 2006-12-05 Biovitrum Ab Bicyclic sulfonamide compounds
WO2003013510A1 (en) * 2001-08-07 2003-02-20 Smithkline Beecham P.L.C. 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
NZ535239A (en) 2002-03-27 2008-03-28 Glaxo Group Ltd Quinoline derivatives and their use as 5-HT6 ligands
TW200400177A (en) * 2002-06-04 2004-01-01 Wyeth Corp 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
EP1897881A3 (de) * 2002-06-20 2009-03-18 Biovitrum AB (publ) Zur Behandlung von Obesitas, Typ II-Diabetes und ZNS-Erkrankungen geeignete Verbindungen
CA2486989A1 (en) * 2002-06-20 2003-12-31 Biovitrum Ab New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
JP4754821B2 (ja) 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
ATE362469T1 (de) * 2002-09-17 2007-06-15 Hoffmann La Roche 2,7-disubstituierteindole und ihre verwendung als 5-ht6 modulatoren
EP1592690A1 (de) 2003-02-14 2005-11-09 Wyeth Heterocyclyl-3-sulfonylazaindol- oder -azaindazolderivate als 5-hydroxytryptamin-6-liganden
AU2004226838B8 (en) 2003-04-04 2009-06-11 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
PL1558582T3 (pl) 2003-07-22 2006-05-31 Arena Pharm Inc Diarylowe i aryloheteroarylowe pochodne mocznika jako modulatory receptora serotoninowego 5-HT2A użyteczne w profilaktyce i w leczeniu zaburzeń związanych z tym receptorem
WO2005060711A2 (en) * 2003-12-19 2005-07-07 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
KR20060127886A (ko) * 2003-12-19 2006-12-13 바이오비트럼 에이비 5-ｈｔ6 수용체-관련 장애의 예방 및 치료에 사용될 수있는, 신규한 벤조퓨란 유도체
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
DE602004014190D1 (de) 2003-12-23 2008-07-10 Lundbeck As Valby H 2-(1h-indolylsulfanyl)-benzylaminderivate als ssri
GB0400895D0 (en) * 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
TW200616967A (en) * 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
AR052308A1 (es) 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
CN101031338B (zh) * 2004-09-30 2013-01-02 弗·哈夫曼-拉罗切有限公司 治疗认知障碍的组合物和方法
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
BRPI0614343A2 (pt) * 2005-08-15 2011-03-22 Wyeth Corp derivados de 3-sulfonilindazol substituìdo como ligantes de 5-hidroxitriptamina-6
ES2274725B1 (es) * 2005-11-08 2008-04-01 Laboratorios Del Dr. Esteve, S.A. Indeno derivados, su preparacion y su uso como medicamentos.
MX2008009022A (es) * 2006-01-13 2008-09-24 Wyeth Corp 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina.
AU2007217040A1 (en) * 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-HT6 receptor affinity
CA2668959A1 (en) * 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Indole and benzofuran 2-carboxamide derivatives
PL2114878T3 (pl) 2007-01-08 2011-05-31 Suven Life Sciences Ltd Związki 5-(heterocyklilo)alkilo-N-(arylosulfonylo)indolowe i ich zastosowanie jako ligandy 5-HT6
CA2672190C (en) * 2007-01-08 2013-02-05 Suven Life Sciences Limited 4-(heterocyclyl)alkyl-n-(arylsulfonyl) indole compounds and their use as 5-ht6 ligands
US20080200471A1 (en) * 2007-02-16 2008-08-21 Memory Pharmaceuticals Corporation 6' substituted compounds having 5-ht6 receptor affinity
JP2010521516A (ja) * 2007-03-21 2010-06-24 グラクソ グループ リミテッド 疼痛および過敏性腸症候群の治療におけるキノリン誘導体の使用
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
WO2008136017A1 (en) 2007-05-03 2008-11-13 Suven Life Sciences Limited Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands
US20080318941A1 (en) * 2007-05-24 2008-12-25 Memory Pharmaceuticals Corporation 4' substituted compounds having 5-ht6 receptor affinity
CA2695456A1 (en) * 2007-08-15 2009-02-19 Robert Dunn 3' substituted compounds having 5-ht6 receptor affinity
CA2703157C (en) 2007-10-26 2013-02-05 Suven Life Sciences Limited Amino arylsulfonamide compounds and their use as 5-ht6 ligands
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
AU2009214190A1 (en) * 2008-02-15 2009-08-20 F. Hoffmann-La Roche Ag 3-alkyl-piperazine derivatives and uses thereof
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) * 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
JP5536781B2 (ja) 2008-09-17 2014-07-02 スヴェン・ライフ・サイエンシズ・リミテッド アリールスルホンアミドアミン化合物および５−ｈｔ６リガンドとしてのそれらの使用
US8318725B2 (en) 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
NZ601284A (en) 2010-01-05 2014-03-28 Suven Life Sciences Ltd Sulfone compounds as 5-ht6 receptor ligands
CN103201262B (zh) 2010-08-20 2016-06-01 艾米拉医药股份有限公司 自分泌运动因子抑制剂及其用途
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
CN102924359B (zh) * 2012-10-30 2015-03-11 中国科学院烟台海岸带研究所 一种一锅法合成取代吲哚类化合物的方法
EP3083588B1 (de) 2013-12-20 2020-12-09 Sunshine Lake Pharma Co., Ltd. Aromatische heterocyclische verbindungen und deren anwendung in pharmazeutika
WO2016004882A1 (en) 2014-07-08 2016-01-14 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
HK1245660A1 (zh) 2015-06-12 2018-08-31 Axovant Sciences Gmbh 有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物
TW201720439A (zh) 2015-07-15 2017-06-16 Axovant Sciences Gmbh 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639752A (en) * 1991-11-25 1997-06-17 Pfizer Inc Indole derivatives
JP3155008B2 (ja) 1994-07-26 2001-04-09 ファイザー・インコーポレーテッド セロトニンアゴニストおよびアンタゴニストとしての４−インドール誘導体
GB9517559D0 (en) * 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
AU732863B2 (en) * 1997-04-18 2001-05-03 Smithkline Beecham Plc Indole derivatives having combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
EP1173432B9 (de) * 1999-04-21 2008-10-15 NPS Allelix Corp. Piperidin-indol derivate mit 5-ht6 affinität
WO2001032660A1 (en) * 1999-11-05 2001-05-10 Nps Allelix Corp. Compounds having 5-ht6 receptor antagonist activity
PL213134B1 (pl) * 2000-11-02 2013-01-31 Wyeth Corp 1-arylo- lub 1-alkilosulfonylo- heterocyklilobenzazole, ich zastosowanie oraz kompozycja farmaceutyczna zawierajaca te zwiazki
US7034029B2 (en) * 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
DK1355900T3 (da) * 2000-12-22 2006-09-11 Wyeth Corp Heterocyclylalkylindol- eller -azaindolforbindelser som 5-hydroxytryptamin-6-ligander
DK1355904T3 (da) * 2000-12-22 2007-10-15 Wyeth Corp Heterocyclindazol- og -azaindazolforbindelser som 5-hydroxytryptamin-6-ligander
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
IL158445A0 (en) * 2001-04-20 2004-05-12 Wyeth Corp Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
WO2003013510A1 (en) * 2001-08-07 2003-02-20 Smithkline Beecham P.L.C. 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
KR20050073560A (ko) * 2002-10-18 2005-07-14 에프. 호프만-라 로슈 아게 5-ｈｔ6 수용체 친화성을 갖는 4-피페라진일 벤젠설폰일인돌

Also Published As

Publication number Publication date
YU96103A (sh) 2006-08-17
RU2294932C2 (ru) 2007-03-10
PE20030039A1 (es) 2003-02-13
US6787535B2 (en) 2004-09-07
SK16052003A3 (en) 2004-10-05
WO2002098857A1 (en) 2002-12-12
CZ20033529A3 (cs) 2004-04-14
NO20035359D0 (no) 2003-12-02
JP2004533460A (ja) 2004-11-04
NZ529631A (en) 2006-08-31
MXPA03011244A (es) 2004-02-27
WO2002098857A8 (en) 2004-04-22
IL158997A0 (en) 2004-05-12
KR20040004702A (ko) 2004-01-13
UY27322A1 (es) 2003-02-28
ES2280546T3 (es) 2007-09-16
PA8546601A1 (es) 2003-01-24
HK1068610A1 (en) 2005-04-29
CO5630036A2 (es) 2006-04-28
US20050171118A1 (en) 2005-08-04
US20030073700A1 (en) 2003-04-17
AU2002310747B2 (en) 2007-10-11
BG108420A (en) 2005-02-28
CN1527816A (zh) 2004-09-08
AR036233A1 (es) 2004-08-25
CA2449874C (en) 2009-06-23
EP1401813B1 (de) 2007-02-07
CA2449874A1 (en) 2002-12-12
DE60218037T2 (de) 2007-08-23
HRP20030984A2 (en) 2005-10-31
RU2003136731A (ru) 2005-05-20
BR0210929A (pt) 2004-06-08
TW591015B (en) 2004-06-11
EP1401813A1 (de) 2004-03-31
CN1257892C (zh) 2006-05-31
US20040248902A1 (en) 2004-12-09
JP4187642B2 (ja) 2008-11-26
DE60218037D1 (de) 2007-03-22
MA27032A1 (fr) 2004-12-20
HUP0401307A2 (hu) 2004-12-28
ZA200309005B (en) 2005-02-21
PL367305A1 (en) 2005-02-21
KR100600240B1 (ko) 2006-07-13

Similar Documents

Publication Publication Date Title
ATE353318T1 (de) Neue indolderivate mit affinität zum 5-ht6- rezeptor
DE60212841D1 (de) 4 piperazinylindolderivate mit affinität zum 5-ht6-rezeptor
DE60309498D1 (de) 4-piperazinylbenzolsulfonyl-indole mit 5-ht6 rezeptor-affinität
DE60328671D1 (de) Neue aminobenzamidderivate
ATE465995T1 (de) N-'(1,5-diphenyl-1h-pyrazol-3- yl)sulfonamidderivate mit affinität zum cb1- rezeptor
DE60336811D1 (de) Neue benzimidazolderivate
DE50105334D1 (de) Neue carbamat-substituierte pyrazolopyridinderivate
DE50202178D1 (de) Neue sulfonat-substituierte pyrazolopyridinderivate
ATE271031T1 (de) Neue phenylpropargyletherderivate
DE50307129D1 (de) Aza-bicyclische n-biarylamide mit affinität zum alpha7 nikotinischen acetylcholin-rezeptor
ATE390430T1 (de) Spirocyclische cyclohexan-derivate mit affinität zum orl1-rezeptor
ATE298752T1 (de) Neue pyridin-substituierte pyrazolopyridinderivate
DE50014679D1 (de) Substituierte indol-mannichbasen
DE60132087D1 (de) Mechanismus zum einstellen der position
DE50111292D1 (de) Neue sulfonamid-substituierte pyrazolopyridinderivate
DE60014662D1 (de) Verbesserungen in der schadstoffausstossregelung
DK1218380T3 (da) Bicykliske imidazo-3-yl-aminoderivater substitueret i seksledsringen
DE60319184D1 (de) Dreirad mit Schwingmechanismus
ATE277077T1 (de) Neue lhrh-antagonisten mit verbesserten löslichkeitseigenschaften
IS7754A (is) Prólín afleiður með sækni fyrir kalkganga alfa-2-delta undireininguna
ATE244716T1 (de) Neue n-triazolylmethyl-piperazinderivate als neurokininrezeptor-antagonisten
NO20015737D0 (no) Indol derivater
DE60111268D1 (de) Neue pleuromutilinderivate
ATE265422T1 (de) Neue phenylheteroalkylamin-derivate
ATE487694T1 (de) Neue phthalamidderivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1401813

Country of ref document: EP

REN Ceased due to non-payment of the annual fee